International Journal of Molecular Sciences Review Steroid Therapy and Steroid Response in Autoimmune Pancreatitis Hiroyuki Matsubayashi 1,2,* , Hirotoshi Ishiwatari 1, Kenichiro Imai 1, Yoshihiro Kishida 1, Sayo Ito 1, Kinichi Hotta 1, Yohei Yabuuchi 1, Masao Yoshida 1, Naomi Kakushima 1, Kohei Takizawa 1, Noboru Kawata 1 and Hiroyuki Ono 1 1 Division of Endoscopy, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan;
[email protected] (H.I.);
[email protected] (K.I.);
[email protected] (Y.K.);
[email protected] (S.I.);
[email protected] (K.H.);
[email protected] (Y.Y.);
[email protected] (M.Y.);
[email protected] (N.K.);
[email protected] (K.T.);
[email protected] (N.K.);
[email protected] (H.O.) 2 Genetic Medicine Promotion, Shizuoka Cancer Center 1007, Shimonagakubo, Nagaizumi, Suntogun, Shizuoka 411-8777, Japan * Correspondence:
[email protected]; Tel.: +81-55-989-5222; Fax: +81-55-989-5692 Received: 25 November 2019; Accepted: 25 December 2019; Published: 30 December 2019 Abstract: Autoimmune pancreatitis (AIP), a unique subtype of pancreatitis, is often accompanied by systemic inflammatory disorders. AIP is classified into two distinct subtypes on the basis of the histological subtype: immunoglobulin G4 (IgG4)-related lymphoplasmacytic sclerosing pancreatitis (type 1) and idiopathic duct-centric pancreatitis (type 2). Type 1 AIP is often accompanied by systemic lesions, biliary strictures, hepatic inflammatory pseudotumors, interstitial pneumonia and nephritis, dacryoadenitis, and sialadenitis. Type 2 AIP is associated with inflammatory bowel diseases in approximately 30% of cases. Standard therapy for AIP is oral corticosteroid administration.